Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Cassandra Gianna Hoffman-LucaShaomeng Wang

Abstract

Two clinical-stage anticancer drugs, the Bcl-2 inhibitor ABT-263, and the MDM2 inhibitor SAR405838 achieve complete tumor regression in animal models of leukemia but also induce acquired resistance. Elucidation of acquired resistance mechanisms and development of strategies to overcome the resistance are critical for their successful clinical development. We employed RS4;11 and MV4;11 cell lines, two acute leukemia models, to investigate acquired resistance mechanisms for both drugs in vitro and in vivo and evaluated several treatment regimens in xenograft mouse models to improve long-term, complete tumor regression. Resistance to either SAR405838 or ABT-263 (or its analogue ABT-737) develops in acute leukemia models in vitro and in vivo. RS4;11 and MV4;11 tumors treated with SAR405838 acquire resistance to the drug by mutation of the TP53 gene or compromise of p53 protein function. RS4;11 tumors treated with either ABT-263 or ABT-737 acquire resistance primarily through downregulation of BAX but not BAK. When acute leukemia cells become highly resistant to the MDM2 inhibitor, they retain their sensitivity to the Bcl-2 inhibitors, or vice versa. Certain sequential or combination treatment of SAR405838 and ABT-263 can achieve lo...Continue Reading

References

Jul 1, 1993·Genes & Development·X WuA J Levine
May 23, 1998·Annual Review of Immunology·D T Chao, S J Korsmeyer
Mar 5, 1999·Cellular and Molecular Life Sciences : CMLS·D A FreedmanA J Levine
Apr 2, 1999·Seminars in Cancer Biology·W S el-Deiry
Aug 13, 1999·Genes & Development·A GrossS J Korsmeyer
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Dec 1, 2000·Nature·B VogelsteinA J Levine
Jan 31, 2002·Annual Review of Medicine·Michael M Gottesman
Aug 3, 2002·Nature Reviews. Cancer·Karen H Vousden, Xin Lu
Sep 5, 2002·Nature Reviews. Cancer·Suzanne Cory, Jerry M Adams
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Dec 10, 2003·Oncogene·Jordan S Fridman, Scott W Lowe
Jan 6, 2004·Science·Lyubomir T VassilevEmily A Liu
Jan 28, 2004·Cell·Nika N Danial, Stanley J Korsmeyer
Feb 22, 2005·Current Cancer Drug Targets·Gareth L BondArnold J Levine
May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
Jul 8, 2005·Journal of Medicinal Chemistry·Lyubomir T Vassilev
Jan 13, 2006·The New England Journal of Medicine·Ching-Hon Pui, William E Evans
Nov 28, 2006·Trends in Molecular Medicine·Lyubomir T Vassilev
Oct 27, 2007·Annals of Clinical Biochemistry·Noriaki MitaniYasuyuki Okamoto
Mar 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sanjeev ShangaryShaomeng Wang
Apr 22, 2008·British Journal of Haematology·Blaine W RobinsonCarolyn A Felix
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Sep 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sanjeev Shangary, Shaomeng Wang
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Jul 19, 2011·Developmental Cell·Jean-Claude Martinou, Richard J Youle
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew W RobertsRod Humerickhouse
Apr 13, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Charles M RudinLeena Gandhi
Apr 9, 2013·Leukemia·A S MooreC M Zwaan

❮ Previous
Next ❯

Citations

Apr 25, 2016·Neoplasia : an International Journal for Oncology Research·Felix Y FengDaniel A Hamstra
Mar 9, 2017·Cold Spring Harbor Perspectives in Medicine·Shaomeng WangChao-Yie Yang
Mar 2, 2019·Expert Opinion on Therapeutic Patents·Lukasz SkalniakTad A Holak
Mar 8, 2017·Proceedings of the National Academy of Sciences of the United States of America·Emilie A ChapeauMichael Rugaard Jensen
Jul 12, 2020·Leukemia·Marina KonoplevaMichael Andreeff
Dec 10, 2019·Journal of Hematology & Oncology·Zuan-Fu Lim, Patrick C Ma
Feb 18, 2017·Cancer Research·Longchuan BaiShaomeng Wang
Oct 3, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne BerberichWolfgang Wick
Feb 26, 2021·Frontiers in Oncology·Matteo MolicaPaolo de Fabritiis
Dec 17, 2021·Cellular & Molecular Biology Letters·Lucia HaronikovaBorivoj Vojtesek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Meike VoglerGerald M Cohen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alex R ShoemakerSteven W Elmore
© 2022 Meta ULC. All rights reserved